Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials
Purpose. Studies investigating efficacy and safety of bevacizumab in pterygium have increased and reported controversial results. Thus, we updated this meta-analysis to clarify the issue. Methods. Studies were selected through search of the databases Embase, PubMed, Web of Science, and the Cochrane...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/4598173 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561311306743808 |
|---|---|
| author | Yi Sun Bowen Zhang Xiuhua Jia Shiqi Ling Juan Deng |
| author_facet | Yi Sun Bowen Zhang Xiuhua Jia Shiqi Ling Juan Deng |
| author_sort | Yi Sun |
| collection | DOAJ |
| description | Purpose. Studies investigating efficacy and safety of bevacizumab in pterygium have increased and reported controversial results. Thus, we updated this meta-analysis to clarify the issue. Methods. Studies were selected through search of the databases Embase, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) from their inception up until June 2017. The pooled risk ratio (RR) and 95% confidence interval (CI) were calculated for recurrence and complication rates by using random effects model. Results. 1045 eyes in 18 randomized controlled trials (RCTs) enrolled. Overall, the pooled estimate showed a statistically significant effect of bevacizumab on the reduction of recurrence (RR 0.74, 95% CI 0.56–0.97, P=0.03). Subgroup analyses presented significant results beneficial to bevacizumab (primary pterygium group, RR 0.53, 95% CI 0.33–0.83, P=0.006; conjunctival autograft group, RR 0.48, 95% CI 0.25–0.91, P=0.02; and follow-up longer than 12 months group, RR 0.36, 95% CI 0.13–0.99, P=0.05). No statistically significant difference was observed in complication rates. Conclusions. Application of bevacizumab showed a statistically significant decrease in recurrence rate following removal of primary pterygia, or in cases with conjunctival autograft, or with follow-up longer than 12 months, while complications were not increased. |
| format | Article |
| id | doaj-art-b1b00c8207e44195b45cc8e1008f8ac0 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-b1b00c8207e44195b45cc8e1008f8ac02025-02-03T01:25:22ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/45981734598173Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled TrialsYi Sun0Bowen Zhang1Xiuhua Jia2Shiqi Ling3Juan Deng4Department of Ophthalmology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, ChinaSurgical Department, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, ChinaDepartment of Ophthalmology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, ChinaDepartment of Ophthalmology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, ChinaDepartment of Ophthalmology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, ChinaPurpose. Studies investigating efficacy and safety of bevacizumab in pterygium have increased and reported controversial results. Thus, we updated this meta-analysis to clarify the issue. Methods. Studies were selected through search of the databases Embase, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) from their inception up until June 2017. The pooled risk ratio (RR) and 95% confidence interval (CI) were calculated for recurrence and complication rates by using random effects model. Results. 1045 eyes in 18 randomized controlled trials (RCTs) enrolled. Overall, the pooled estimate showed a statistically significant effect of bevacizumab on the reduction of recurrence (RR 0.74, 95% CI 0.56–0.97, P=0.03). Subgroup analyses presented significant results beneficial to bevacizumab (primary pterygium group, RR 0.53, 95% CI 0.33–0.83, P=0.006; conjunctival autograft group, RR 0.48, 95% CI 0.25–0.91, P=0.02; and follow-up longer than 12 months group, RR 0.36, 95% CI 0.13–0.99, P=0.05). No statistically significant difference was observed in complication rates. Conclusions. Application of bevacizumab showed a statistically significant decrease in recurrence rate following removal of primary pterygia, or in cases with conjunctival autograft, or with follow-up longer than 12 months, while complications were not increased.http://dx.doi.org/10.1155/2018/4598173 |
| spellingShingle | Yi Sun Bowen Zhang Xiuhua Jia Shiqi Ling Juan Deng Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials Journal of Ophthalmology |
| title | Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_full | Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_fullStr | Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_full_unstemmed | Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_short | Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials |
| title_sort | efficacy and safety of bevacizumab in the treatment of pterygium an updated meta analysis of randomized controlled trials |
| url | http://dx.doi.org/10.1155/2018/4598173 |
| work_keys_str_mv | AT yisun efficacyandsafetyofbevacizumabinthetreatmentofpterygiumanupdatedmetaanalysisofrandomizedcontrolledtrials AT bowenzhang efficacyandsafetyofbevacizumabinthetreatmentofpterygiumanupdatedmetaanalysisofrandomizedcontrolledtrials AT xiuhuajia efficacyandsafetyofbevacizumabinthetreatmentofpterygiumanupdatedmetaanalysisofrandomizedcontrolledtrials AT shiqiling efficacyandsafetyofbevacizumabinthetreatmentofpterygiumanupdatedmetaanalysisofrandomizedcontrolledtrials AT juandeng efficacyandsafetyofbevacizumabinthetreatmentofpterygiumanupdatedmetaanalysisofrandomizedcontrolledtrials |